IceCure Medical (NASDAQ:ICCM) Stock Price Down 1.6% – Time to Sell?

IceCure Medical Ltd (NASDAQ:ICCM) traded down 1.6% during mid-day trading on Monday . The stock traded as low as $1.19 and last traded at $1.22. 205,121 shares were traded during trading, a decline of 52% from the average session volume of 430,251 shares. The stock had previously closed at $1.24.

Analyst Ratings Changes

ICCM has been the subject of a number of recent research reports. Alliance Global Partners upgraded shares of IceCure Medical to a “strong-buy” rating in a report on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and issued a $2.50 price target on shares of IceCure Medical in a report on Wednesday, November 27th.

IceCure Medical Stock Performance

The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.27 and a current ratio of 2.67. The firm’s 50-day moving average price is $1.03 and its two-hundred day moving average price is $0.79. The stock has a market cap of $67.71 million, a price-to-earnings ratio of -4.21 and a beta of 0.37.

IceCure Medical (NASDAQ:ICCM) last announced its quarterly earnings results on Tuesday, November 26th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. On average, analysts expect that IceCure Medical Ltd will post -0.28 EPS for the current fiscal year.

Institutional Trading of IceCure Medical

A hedge fund recently bought a new stake in IceCure Medical stock. Renaissance Technologies LLC bought a new position in shares of IceCure Medical Ltd (NASDAQ:ICCM) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 66,400 shares of the company’s stock, valued at approximately $49,000. Renaissance Technologies LLC owned 0.15% of IceCure Medical at the end of the most recent reporting period. 0.62% of the stock is currently owned by hedge funds and other institutional investors.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.